Sanofi will license its research into infectious diseases and its
early-stage development portfolio, and the French group will also
transfer its research unit dealing with this area over to Evotec.
Sanofi will pay Evotec an initial one-time cash upfront payment of
60 million euros ($74.4 million) and provide further significant
long-term funding to develop portfolio, the companies added.
(Reporting by Sudip Kar-Gupta; Editing by Gopakumar Warrier)
[© 2018 Thomson Reuters. All rights
reserved.] Copyright 2018 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed.
Thompson Reuters is solely responsible for this content. |